These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 26856846)

  • 1. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.
    Rigatto MH; Oliveira MS; Perdigão-Neto LV; Levin AS; Carrilho CM; Tanita MT; Tuon FF; Cardoso DE; Lopes NT; Falci DR; Zavascki AP
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2443-9. PubMed ID: 26856846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
    Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
    Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colistin versus polymyxin B: A pragmatic assessment of renal and neurological adverse effects and effectiveness in multidrug-resistant Gram-negative bacterial infections.
    Simon V; Viswam A; Alexander PS; James E; Sudhindran S
    Indian J Pharmacol; 2023; 55(4):229-236. PubMed ID: 37737075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia.
    Omrani AS; Alfahad WA; Shoukri MM; Baadani AM; Aldalbahi S; Almitwazi AA; Albarrak AM
    Ann Clin Microbiol Antimicrob; 2015 Jan; 14():3. PubMed ID: 25591721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis.
    Vardakas KZ; Falagas ME
    Int J Antimicrob Agents; 2017 Feb; 49(2):233-238. PubMed ID: 27686609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.
    Crass RL; Rutter WC; Burgess DR; Martin CA; Burgess DS
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.
    Karaiskos I; Friberg LE; Pontikis K; Ioannidis K; Tsagkari V; Galani L; Kostakou E; Baziaka F; Paskalis C; Koutsoukou A; Giamarellou H
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7240-8. PubMed ID: 26369974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study.
    Rigatto MH; Behle TF; Falci DR; Freitas T; Lopes NT; Nunes M; Costa LW; Zavascki AP
    J Antimicrob Chemother; 2015 May; 70(5):1552-7. PubMed ID: 25604744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetics of Colistin Methanesulfonate and Colistin in Critically Ill Patients with Acute Renal Failure Requiring Intermittent Hemodialysis.
    Jacobs M; Grégoire N; Mégarbane B; Gobin P; Balayn D; Marchand S; Mimoz O; Couet W
    Antimicrob Agents Chemother; 2016 Jan; 60(3):1788-93. PubMed ID: 26729492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrotoxicity Associated with Intravenous Polymyxin B Once- versus Twice-Daily Dosing Regimen.
    Okoduwa A; Ahmed N; Guo Y; Scipione MR; Papadopoulos J; Eiras DP; Dubrovskaya Y
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center.
    Akajagbor DS; Wilson SL; Shere-Wolfe KD; Dakum P; Charurat ME; Gilliam BL
    Clin Infect Dis; 2013 Nov; 57(9):1300-3. PubMed ID: 23840000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Toxicity of High-Dose Colistin in Multidrug-Resistant Gram-Negative Bacilli Infections: A Comparative Study of a Matched Series.
    Trifi A; Abdellatif S; Daly F; Mahjoub K; Nasri R; Oueslati M; Mannai R; Bouzidi M; Ben Lakhal S
    Chemotherapy; 2016; 61(4):190-6. PubMed ID: 26863534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe Infusion-Related Adverse Events and Renal Failure in Patients Receiving High-Dose Intravenous Polymyxin B.
    John JF; Falci DR; Rigatto MH; Oliveira RD; Kremer TG; Zavascki AP
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colistin-associated Acute Kidney Injury in Severely Ill Patients: A Step Toward a Better Renal Care? A Prospective Cohort Study.
    Dalfino L; Puntillo F; Ondok MJ; Mosca A; Monno R; Coppolecchia S; Spada ML; Bruno F; Brienza N
    Clin Infect Dis; 2015 Dec; 61(12):1771-7. PubMed ID: 26354965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymyxin B vs. colistin: the comparison of neurotoxic and nephrotoxic effects of the two polymyxins.
    Aysert-Yildiz P; Özgen-Top Ö; Şentürk AF; Kanik S; Özger HS; Dizbay M
    BMC Infect Dis; 2024 Aug; 24(1):862. PubMed ID: 39187812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?
    Zavascki AP; Nation RL
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.
    Phe K; Lee Y; McDaneld PM; Prasad N; Yin T; Figueroa DA; Musick WL; Cottreau JM; Hu M; Tam VH
    Antimicrob Agents Chemother; 2014 May; 58(5):2740-6. PubMed ID: 24566187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of nephrotoxicity of Colistin with Polymyxin B administered in currently recommended doses: a prospective study.
    Aggarwal R; Dewan A
    Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):15. PubMed ID: 29571295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colistin- and polymyxin-induced nephrotoxicity: focus on literature utilizing the RIFLE classification scheme of acute kidney injury.
    Pike M; Saltiel E
    J Pharm Pract; 2014 Dec; 27(6):554-61. PubMed ID: 25237156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of Colistin Dose on Global Cure in Patients with Bacteremia Due to Carbapenem-Resistant Gram-Negative Bacilli.
    Gibson GA; Bauer SR; Neuner EA; Bass SN; Lam SW
    Antimicrob Agents Chemother; 2016 Jan; 60(1):431-6. PubMed ID: 26525802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.